SLC6A3 binds DRIs

Stable Identifier
R-HSA-9714580
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Synonyms
SLC6A3 binds SLC6A3 inhibitors, DAT binds DRIs
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT, aka SLC6A3) (Tatsumi et al. 1997, Richelson 2001). The result is increased extracellular concentrations of dopamine and an increase in dopaminergic neurotransmission. DRIs are used in the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy for their psychostimulant effects (eg. bupropion, dexamfetamine, dexmethylphenidate and methyphenidate), and in the treatment of obesity and binge eating disorder for their appetite suppressant effects (eg. mazindol). Trimipramine has antihistamine, antiserotonergic, antiadrenergic, antidopaminergic, and anticholinergic activities but is primarily used to treat depression, anxiety and insomnia (Pecknold & Luthe 1989).
Literature References
PubMed ID Title Journal Year
11357798 Pharmacology of antidepressants

Richelson, E

Mayo Clin Proc 2001
9537821 Pharmacological profile of antidepressants and related compounds at human monoamine transporters

Blakely, RD, Tatsumi, M, Richelson, E, Groshan, K

Eur J Pharmacol 1997
Participants
Participates
Orthologous Events
Authored
Reviewed
Created
Cite Us!